Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTEROID trial: SBRT followed by durvalumab in stage I NSCLC
2016-005225-37Phase 2Active
- Sponsor
- Sahlgrenska University Hospital
- Start
- Jun 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Durvalumab after SBRT with SBRT alone (observation) (2 arms). Primary endpoint: Time to Progression. Started Jun 2018; status: active.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2016-005225-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005225-37.